Your browser doesn't support javascript.
loading
Inclusion of functional measures and frailty in the development and evaluation of medicines for older adults.
Denkinger, Michael; Knol, Wilma; Cherubini, Antonio; Simonds, Anita; Lionis, Christos; Lacombe, Denis; Petelos, Elena; McCarthy, Mary; Ouvrard, Patrick; Van Kerrebroeck, Philip; Szymanski, Piotr; Cupelli, Amelia; Laslop, Andrea; Koch, Armin; Sepodes, Bruno; Torre, Carla; Rönnemaa, Elina; Balkowiec-Iskra, Ewa; Herdeiro, Maria Teresa; Rosa, Mário Miguel; Trauffler, Martine; Mirosevic Skvrce, Nikica; Mayrhofer, Sabine; Berntgen, Michael; Silva, Ivana; Cerreta, Francesca.
Afiliación
  • Denkinger M; European Geriatric Medicine Society, Genoa, Italy; Institute for Geriatric Research, Ulm University Medical Center at Agaplesion Bethesda Ulm, Ulm, Germany. Electronic address: michael.denkinger@agaplesion.de.
  • Knol W; European Geriatric Medicine Society, Genoa, Italy; Department of Geriatric Medicine, University Medical Centre Utrecht, Utrecht University, Utrecht, Netherlands.
  • Cherubini A; European Geriatric Medicine Society, Genoa, Italy; Geriatria, Accettazione geriatrica e Centro di ricerca per l'invecchiamento, IRCCS INRCA, Ancona, Italy.
  • Simonds A; European Respiratory Society, Lausanne, Switzerland; NIHR Respiratory Biomedical Research Unit, Royal Brompton & Harefield NHS Foundation Trust, London, UK.
  • Lionis C; European Forum for Primary Care, Utrecht, Netherlands; Clinic of Social and Family Medicine, Faculty of Medicine, University of Crete, Heraklion, Greece.
  • Lacombe D; European Organisation for Research and Treatment of Cancer, Brussels, Belgium.
  • Petelos E; European Forum for Primary Care, Utrecht, Netherlands; Clinic of Social and Family Medicine, Faculty of Medicine, University of Crete, Heraklion, Greece; European Public Health Association, Utrecht, Netherlands; Health Services Research, Care and Public Health Research Institute, Faculty of Health,
  • McCarthy M; European Union of General Practitioners/Family Physicians, Brussels, Belgium.
  • Ouvrard P; European Union of General Practitioners/Family Physicians, Brussels, Belgium; Société de Formation Thérapeutique du Généraliste, Paris, France.
  • Van Kerrebroeck P; Department of Urology, Maastricht University, Maastricht, Netherlands; European Association of Urology, Arnhem, Netherlands.
  • Szymanski P; European Society of Cardiology, Sophia Antipolis Cedex, France; Center for Clinical Cardiology, Structural and Rare Cardiovascular Diseases, National Institute of Medicine MSWiA, Warsaw, Poland.
  • Cupelli A; Pharmacovigilance Risk Assessment Committee, European Medicines Agency, Amsterdam, Netherlands; Pharmacovigilance Office, Italian Medicines Agency, Rome, Italy.
  • Laslop A; Pharmacovigilance Risk Assessment Committee, European Medicines Agency, Amsterdam, Netherlands; Scientific Office, Austrian Medicines and Medical Devices Agency, Federal Office for Safety in Health Care, Vienna, Austria.
  • Koch A; Institut für Biometrie, Medizinische Hochschule Hannover, Hanover, Germany.
  • Sepodes B; Committee for Medicinal Products for Human Use, European Medicines Agency, Amsterdam, Netherlands; Departamento de Farmácia, Farmacologia e Tecnologias em Saúde, Faculdade de Farmácia, Universidade de Lisboa, Lisbon, Portugal.
  • Torre C; Committee for Medicinal Products for Human Use, European Medicines Agency, Amsterdam, Netherlands; Departamento de Farmácia, Farmacologia e Tecnologias em Saúde, Faculdade de Farmácia, Universidade de Lisboa, Lisbon, Portugal.
  • Rönnemaa E; Scientific Advice Working Party, European Medicines Agency, Amsterdam, Netherlands; Department of Public Health and Caring Sciences/Geriatrics, Uppsala, Sweden.
  • Balkowiec-Iskra E; Committee for Medicinal Products for Human Use, European Medicines Agency, Amsterdam, Netherlands; Scientific Advice Working Party, European Medicines Agency, Amsterdam, Netherlands; Central Nervous System Working Party, European Medicines Agency, Amsterdam, Netherlands; The Office for Registration
  • Herdeiro MT; Pharmacovigilance Risk Assessment Committee, European Medicines Agency, Amsterdam, Netherlands; Health Sciences Department Institute of Biomedicine, University of Aveiro, Aveiro, Portugal.
  • Rosa MM; Scientific Advice Working Party, European Medicines Agency, Amsterdam, Netherlands; Centro de Estudos Egas Moniz, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
  • Trauffler M; Committee for Medicinal Products for Human Use, European Medicines Agency, Amsterdam, Netherlands; Division of Pharmacy and Medicines, Directorate of Health, Ministry of Health, Luxembourg.
  • Mirosevic Skvrce N; Pharmacovigilance Risk Assessment Committee, European Medicines Agency, Amsterdam, Netherlands; Pharmacovigilance Department, Agency for Medicinal Products and Medical Devices, Zagreb, Croatia.
  • Mayrhofer S; Committee for Medicinal Products for Human Use, European Medicines Agency, Amsterdam, Netherlands; Federal Institute for Drugs and Medical Devices, Bonn, Germany.
  • Berntgen M; Scientific Evidence Generation Department, European Medicines Agency, Amsterdam, Netherlands.
  • Silva I; Public and Stakeholders Department, European Medicines Agency, Amsterdam, Netherlands.
  • Cerreta F; Scientific Evidence Generation Department, European Medicines Agency, Amsterdam, Netherlands.
Lancet Healthy Longev ; 4(12): e724-e729, 2023 12.
Article en En | MEDLINE | ID: mdl-37977177
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Fragilidad Límite: Aged / Aged80 / Humans Idioma: En Revista: Lancet Healthy Longev Año: 2023 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Fragilidad Límite: Aged / Aged80 / Humans Idioma: En Revista: Lancet Healthy Longev Año: 2023 Tipo del documento: Article Pais de publicación: Reino Unido